Platelets and Coagulation Pathways

Platelets play a crucial role in blood coagulation processes.
Understanding coagulation requires distinguishing between two primary pathways: extrinsic and intrinsic pathways, both converging into the common pathway.

Involves Factors III (tissue factor) and VII.
Known for its speed in activation.
Mnemonic: "Get out on Highway 37" to remember it's faster and has fewer factors.

Composed of Factors XII, XI, IX, and VIII.
Activation of Factor XII is the starting point for this pathway.
Mnemonic: "For twelve, I'll settle for eleven, ninety-eight" to help remember the sequence.

Involves Factors X, V, II (prothrombin), and I (fibrinogen).
Factor X gets converted to Xa, activating prothrombin to thrombin (Factor IIa).
Thrombin facilitates the conversion of fibrinogen to fibrin, leading to clot formation.
Mnemonic: "Ten and five open the door, two and one hit the floor" refers to the critical factors involved in stabilization.

Prothrombin Time (PT): measures the extrinsic pathway.
- Normal range: 11-13.5 seconds.
- Mnemonic: "Play Tennis" (activities outside).
- Monitored for patients on anticoagulation therapy like Warfarin.
Partial Thromboplastin Time (PTT): measures the intrinsic pathway.
- Normal range: 25-35 seconds.
- Mnemonic: "Play Table Tennis" (activities inside).
- Monitored for patients on heparin.
International Normalized Ratio (INR): standardizes PT results.
- Normal INR is 0.8-1.2 for patients not on anticoagulants, higher for those on Warfarin to ensure therapeutic efficacy without excessive bleeding.
Fibrinogen: normal levels are typically between 200-400 mg/dL.
D-dimer: measures fibrinolysis and is elevated in clot breakdown situations such as DVTs (Deep Venous Thrombosis).

The liver synthesizes most clotting factors and produces bile needed for vitamin K absorption.
Liver disease leads to decreased clotting factors, fibrinogen, and defective vitamin K absorption, increasing bleeding risk.
Management may include Vitamin K injections and fresh frozen plasma administration.

Defined as a low platelet count, which can lead to impaired hemostasis and increased bleeding risk.
Causes: May result from decreased production in the bone marrow (e.g., due to chemotherapy, bone marrow disorders, viral infections) or increased destruction/sequestration (e.g., immune thrombocytopenia, DIC, splenomegaly).
Symptoms: Often include petechiae, purpura, easy bruising, nosebleeds (epistaxis), and gum bleeding.
Management: Depends on the underlying cause and severity. It may involve platelet transfusions, corticosteroids, or immunoglobulin therapy.

A group of inherited genetic disorders that impair the body's ability to make blood clots, a process needed to stop bleeding.
Types:
- Hemophilia A: Deficiency in Factor VIII. Most common type.
- Hemophilia B: Deficiency in Factor IX. Also known as Christmas disease.
- Hemophilia C: Deficiency in Factor XI. Less severe than A or B.
Symptoms: Characterized by prolonged bleeding episodes after injury, surgery, or even spontaneously, especially into joints and muscles.
Management: Primarily involves replacement therapy of the deficient clotting factor, either on demand to stop bleeding or prophylactically to prevent bleeding episodes. Desmopressin may be used for mild Hemophilia A.